Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. - Wikidata - awgldk - TriplyDB

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

http://www.wikidata.org/entity/Q34065725

about

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis Metabolic factors and chronic hepatitis C: a complex interplay Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B.IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT.Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.The impact of host factors on management of hepatitis C virus.A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients.The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2.Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection.Individualization of chronic hepatitis C treatment according to the host characteristics.The recent breakthroughs in the understanding of host genomics in hepatitis C.IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.Cholesterol and chronic hepatitis C virus infection.IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Metabolic alterations and chronic hepatitis C: treatment strategies.Host genomics and HCV treatment response.Genetics of IL28B and HCV--response to infection and treatment.Lipids and HCV.Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?Review article: genetic factors that modify the outcome of viral hepatitis.Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response.Genotype 3 Infection: The Last Stand of Hepatitis C Virus.Insulin resistance, steatosis and hepatitis C virus.Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.

P2860

Q26798151-0A7A08D3-94BB-46D2-BC6B-69DCD57028B2 Q27011787-F108926C-F5F5-42D1-B145-F98A072BC6FE Q28081216-1E1A9D1E-D214-4D11-BB3C-3F81E652679D Q28480392-DB3D4282-6C88-41ED-9088-5B02B1CAA5B5 Q28483964-C43862CF-A5A5-409D-A207-73F5334C525A Q33599325-AAA4B2EF-31BD-4E6E-ABAC-B0A5E2A50606 Q33803007-9FF08EDB-279F-4FAF-9478-2600799C5EBE Q33959591-890D6B59-94A3-49F6-9056-0A8F2797F45A Q34075388-5BD7131F-5A18-4753-92D5-729FB01819E1 Q34142463-B6E2FF2A-2351-466B-B855-A762D8FB6FBB Q34923937-DFAB1ABB-1CF3-4913-B8F4-6FE62464E679 Q35027939-707352E0-0E06-4542-AB3D-8011D5020AB3 Q35094287-F255CFEA-A9B7-43BA-B429-9E232CDCC0F6 Q35122925-27BBBF40-A01E-4F8E-AD45-2B3C4CF5FF9C Q35164100-DF5C7007-B952-498C-B597-2ACBCFDAB020 Q35990066-179CCB9F-9770-4043-A3D9-B0F8DA970388 Q36092768-AD87E371-DE35-48CA-A0AD-5AE4D81A4758 Q36185375-A405A6B6-7A35-4D29-BAD8-9B04A007884A Q36208380-7C3DF0DE-1FE9-42DB-AF4F-CC350F8269A3 Q36410947-5C1D13F2-A172-4383-BE52-B5F040CC7D13 Q36457831-37B11EFB-740D-4808-A563-13645E8D63FA Q37015738-D95F44C7-F674-4AD1-92C8-493D9197D463 Q37149463-F8C0224A-0C32-47A3-BC1B-434D4FC2335C Q37285273-77010B3F-6E9D-4FA2-8F6B-A866778EB571 Q37654502-719FF5E2-B86F-47C2-AE3A-81650936EF8C Q37771963-8E99CCF3-5264-44E0-B19B-8870C27C019B Q37773168-385C8E2C-96B7-4EC0-B5E0-C3DC4FF7AA83 Q37879701-1FD01BE1-C71C-4546-B156-A0A42FD36AA3 Q37891171-C0644F65-3626-4FBE-A4DD-76C2D34AA2FD Q37921307-13B260E8-CC09-4DEA-B5E2-EC9EA2CFE493 Q37924816-A7241679-B442-4FDC-BB1D-88047A3AFF5A Q37932036-58C3C1F1-0E55-4E83-8F1C-52BAE92EFE41 Q38013941-C38AC3EC-8848-42F9-9A79-E7DF4C3136BE Q38056643-E5B5CC29-241A-4C0F-A5F6-308989E63362 Q38170504-774F39B9-0224-4B70-B3EE-5AAFFFDA19EE Q38198089-74D137FA-DCB6-43FA-8CE5-78FC330C5DF4 Q38584278-EB2B95E2-4CF8-4E32-9EC3-3B59329A73DC Q38772047-80FE74D4-F8F0-4877-B69D-3827EDBC0449 Q39240971-104A9016-D2B9-4C2F-8F33-EF11455C84BB Q39380623-477D5B47-3E49-40E7-ACCA-634B4DA1DB85

P2860

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

http://www.wikidata.org/entity/Q34065725

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@ast

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@en

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@nl

type

label

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@ast

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@en

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@nl

prefLabel

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@ast

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@en

Interferon-lambda genotype and ...... chronic hepatitis C infection.

@nl

P1433

Q34065725-60EC6CED-0D19-47FA-AB1A-3BCF35967A66

P1476

Q34065725-8AAD1500-2497-4BFC-9350-CF5B0CFF6F86

P2093

Q34065725-05E0463F-1D96-4391-94E1-208A2662EDDE

Q34065725-084827C9-2435-4DB0-B1C5-65EA13CEE2EF

Q34065725-110AA1D0-119D-44AB-B275-5993AE45E0DA

Q34065725-337C01F8-42C2-4094-A68F-9AFC77ECE34C

Q34065725-43AFCDA4-6B6B-4ECD-882F-AD85D11D2AEB

Q34065725-4ACEF948-760D-4934-AA25-E0BC735CAFEA

Q34065725-649F681A-8231-4378-AC07-F9426B7F20DA

Q34065725-6FCA4A5C-09A5-41B1-8B7A-0B47416C7FFF

Q34065725-F76E62E3-18B6-4EC9-8A1F-ACE81DEC587F

Q34065725-F9D8D042-9116-45FA-903B-006A39D61B2F

P2860

Q34065725-018CD74B-D493-40B0-8621-562E0A8CDE35

Q34065725-0873B152-F51A-484B-8D37-506902C833FD

Q34065725-1CF46486-EAED-4F58-8283-9E4572A80887

Q34065725-25DDCA8A-DE74-4E14-AC51-12F7C0F13C1E

Q34065725-33188301-2C03-4CF5-8E2E-54D115008784

Q34065725-335EAD33-31D8-4450-BD88-0851B592C53E

Q34065725-3608AE92-4EBE-48FD-982C-ADFC91750848

Q34065725-3988168E-4EDE-4282-AC84-20C91081C3AD

Q34065725-581D5055-DBD5-40CB-BF69-ABA64FD2689C

Q34065725-6C80BC0E-E7E6-4EA6-AED5-4D2E6F14CC2B

P304

Q34065725-97AF759F-1646-409A-A8B3-EEDCAA8F9614

P31

Q34065725-6923641C-D88F-402E-9020-8BF8905F96D0

P356

Q34065725-61DDC8C8-FB37-48B5-9CF1-13A09C4ED49B

P407

Q34065725-CEB01CB6-3927-4033-9D95-13C36F5FE63D

P433

Q34065725-9446433F-1B13-4559-BBED-7B907E118CAA

P478

Q34065725-37D21297-70DE-469E-9394-64766430D105

P50

Q34065725-7C2A544E-25DA-470B-BE38-9A7DA6A7844F

Q34065725-DD53C16A-32B1-459A-AC58-5BFA59E4BD4B

P577

Q34065725-74F92E1C-D649-498E-8D4B-22D992674E10

P5875

Q34065725-4C5AAB4D-864B-4E1E-8132-B0964D371C69

P698

Q34065725-4D49DEC1-59CA-4D98-848E-CBA8970F12BC

P921

Q34065725-4B963C05-21E2-4128-8618-249C68EFC080

Q34065725-72108A56-0651-4A70-B203-13F67BEE0E4A

Q34065725-F6F81149-B878-4F6D-AADD-2A05F2D23B60

P932

Q34065725-0E17EA7D-DCD4-4621-9501-BFD1E5A9C50B

P356

P1433

P1476

Interferon-lambda genotype and ...... chronic hepatitis C infection

@en

P2093

Alexander Thompson

http://www.w3.org/2001/XMLSchema#string

Andrew J Muir

http://www.w3.org/2001/XMLSchema#string

Hans L Tillmann

http://www.w3.org/2001/XMLSchema#string

Jeanette J McCarthy

http://www.w3.org/2001/XMLSchema#string

Jennifer Rowell

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Josephine H Li

http://www.w3.org/2001/XMLSchema#string

Keyur Patel

http://www.w3.org/2001/XMLSchema#string

Stephen D Gardner

http://www.w3.org/2001/XMLSchema#string

Sunil Suchindran

http://www.w3.org/2001/XMLSchema#string

P2860

Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus

Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

Interferon signaling and treatment outcome in chronic hepatitis C

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

P304

1904-1911

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23592

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42110397

http://www.w3.org/2001/XMLSchema#string

P698

20235331

http://www.w3.org/2001/XMLSchema#string

P921

LDL cholesterol

P932

2921623

http://www.w3.org/2001/XMLSchema#string